国际标准期刊号: ISSN 2472-016X

骨科肿瘤学杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Chemotherapy's Role in Bone Cancer Treatment

Montana Mafia*

Chemotherapy plays a pivotal role in the comprehensive treatment of bone cancer, a rare and aggressive malignancy that poses significant challenges to patients and healthcare providers. As a systemic treatment, chemotherapy utilizes potent drugs to target and destroy rapidly dividing cancer cells, inhibiting tumor growth and preventing metastasis. In bone cancer treatment, chemotherapy serves multiple crucial functions, including neoadjuvant therapy to shrink tumors before surgery, adjuvant therapy to eradicate residual cancer cells post-surgery and palliative care to alleviate symptoms and improve the quality of life for advanced-stage patients. Through ongoing research and clinical advancements, chemotherapy for bone cancer has evolved, leading to more targeted and personalized therapies, thereby reducing side effects and enhancing treatment efficacy. Challenges persist; however, as bone cancer’s aggressive nature and potential drug resistance necessitate continued investigation and innovative approaches. The pursuit of further research, multidisciplinary collaboration, and precision medicine holds promise for continually refining chemotherapy’s role in bone cancer treatment, offering hope and improved outcomes for patients facing this formidable disease [1].